INSMED Inc. Files 8-K on Operations and Financials

Ticker: INSM · Form: 8-K · Filed: 2025-08-07T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financial-condition, operations

Related Tickers: INSM

TL;DR

INSMED filed an 8-K on Aug 7th detailing financial condition and operations.

AI Summary

On August 7, 2025, INSMED Incorporated filed an 8-K report to disclose information regarding its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Virginia and its principal executive offices are located in Bridgewater, New Jersey.

Why It Matters

This 8-K filing provides investors with crucial updates on INSMED Inc.'s operational performance and financial health, enabling informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for operational and financial updates, not indicating any immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on INSMED Inc.'s results of operations and financial condition, and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 7, 2025.

In which state is INSMED Inc. incorporated?

INSMED Inc. is incorporated in Virginia.

What is the address of INSMED Inc.'s principal executive offices?

The address of INSMED Inc.'s principal executive offices is 700 US Highway 202/206, Bridgewater, New Jersey 08807.

What is the SIC code for INSMED Inc.?

The Standard Industrial Classification (SIC) code for INSMED Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-08-07 07:01:55

Key Financial Figures

Filing Documents

02 — Results of Operations and Financial Condition

ITEM 2.02 — Results of Operations and Financial Condition. On August 7, 2025, Insmed Incorporated (the "Company") issued a press release regarding its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02 and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2. The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Financial Statements and Exhibits

ITEM 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Insmed Incorporated on August 7, 2025. 99.2 Insmed Incorporated August 7, 2025 Presentation. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2025 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing